$2.48
15.35% yesterday
Nasdaq, Dec 29, 10:18 pm CET
ISIN
US6963891055
Symbol
PALI

Palisade Bio Inc Stock price

$2.48
+0.61 32.62% 1M
+1.80 264.65% 6M
+0.83 50.30% YTD
+0.78 45.88% 1Y
-45.82 94.87% 3Y
-3,689.32 99.93% 5Y
-1,228,497.52 100.00% 10Y
-2,339,997.52 100.00% 20Y
Nasdaq, Closing price Mon, Dec 29 2025
+0.33 15.35%
ISIN
US6963891055
Symbol
PALI
Industry

Key metrics

Basic
Market capitalization
$320.4m
Enterprise Value
$315.3m
Net debt
positive
Cash
$5.2m
Shares outstanding
9.1m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
99.8
Financial Health
Equity Ratio
68.9%
Return on Equity
-192.7%
ROCE
-
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | -
EBIT
- | $-12.9m
Net Income
- | $-10.9m
Free Cash Flow
$-10.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | 13.2%
Net Income
- | 24.9%
Free Cash Flow
19.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-1.1
Short interest
8.6%
Employees
8
Rev per Employee
$0.0
Show more

Is Palisade Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Palisade Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Palisade Bio Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Palisade Bio Inc forecast:

Buy
89%
Hold
11%

Financial data from Palisade Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.80 5.80
6% 6%
-
- Research and Development Expense 9.06 9.06
31% 31%
-
-15 -15
16% 16%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
16% 16%
-
Net Profit -14 -14
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Palisade Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Palisade Bio Inc Stock News

Positive
Seeking Alpha
7 days ago
Palisade Bio's bull thesis centers on PALI-2108. This is a gut-targeted PDE4 prodrug aiming for local efficacy with fewer systemic PDE4 side effects. The main target indications are UC and FSCD, which promise a sizable TAM if PALI-2108 ultimately succeeds. Naturally, this means PALI's story remains early-stage and highly data-dependent. Yet, they have a compelling near-term catalyst stack.
Neutral
GlobeNewsWire
28 days ago
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease
Neutral
GlobeNewsWire
about one month ago
Live webcast fireside chat on Thursday, December 4 th at 10:30 AM ET Carlsbad, CA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced JD Finley, Chief Executive Officer...
More Palisade Bio Inc News

Company Profile

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company is headquartered in Carlsbad, CA.

Head office United States
CEO J. Finley
Employees 8
Founded 2011
Website palisadebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today